Faeth Therapeutics Stock (NASDAQ:FTH)


Chart

Previous Close

$25.00

52W Range

$6.33 - $36.76

50D Avg

$21.14

200D Avg

$17.02

Market Cap

$31.75M

Avg Vol (3M)

$55.37K

Beta

-0.23

Div Yield

-

FTH Company Profile


Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Aug 11, 2014

Website

FTH Performance


Peer Comparison


TickerCompany
MRKRMarker Therapeutics, Inc.
DWTXDogwood Therapeutics, Inc.
BOLTBolt Biotherapeutics, Inc.
EVGNEvogene Ltd.
COCPCocrystal Pharma, Inc.
IMNNImunon, Inc.
CINGCingulate Inc.
CLRBCellectar Biosciences, Inc.
TRAWTraws Pharma, Inc.